Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer

Authors:
  • MNMasahiro Natsuaki
    Masahiro Natsuaki
  • KKKen Kozuma
    Ken Kozuma
  • TMTakeshi Morimoto
    Takeshi Morimoto
  • KKKazushige Kadota
    Kazushige Kadota
  • TMToshiya Muramatsu
    Toshiya Muramatsu
  • YNYoshihisa Nakagawa
    Yoshihisa Nakagawa
  • TATakashi Akasaka
    Takashi Akasaka
  • KIKeiichi Igarashi
    Keiichi Igarashi
  • KTKengo Tanabe
    Kengo Tanabe
  • YMYoshihiro Morino
    Yoshihiro Morino
  • TITetsuya Ishikawa
    Tetsuya Ishikawa
  • HNHideo Nishikawa
    Hideo Nishikawa

Abstract
Background—: There is a paucity of data reporting the clinical outcomes of biodegradable polymer biolimus-eluting stent (BP-BES) compared with durable polymer everolimus-eluting stent (DP-EES) beyond 1 year after stent implantation when the polymer is fully degraded. Methods and Results—: The NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial (NEXT) is a prospective, multicenter, randomized, open-label, noninferiority trial comparing BP-BES with DP-EES in patients scheduled for percutaneous coronary intervention using drug-eluting stent (DES) without any exclusion criteria among 98 participating centers in Japan. The trial was designed to evaluate noninferiority of BP-BES relative to DP-EES in terms of any target-lesion revascularization at 1 year and death or myocardial infarction at 3 years. Between May and October 2011, 3235 patients were randomly assigned to receive either BP-BES (1617 patients) or DP-EES (1618 patients). Complete 3-year follow-up was achieved in 97.6% of patients. At 3 years, the primary safety end point of death or myocardial infarction occurred in 159 patients (9.9%) in the BP-BES group and in 166 patients (10.3%) in the DP-EES group, demonstrating noninferiority of BP-BES relative to DP-EES ( P noninferiorityP superiority=0.7). Cumulative incidence of target-lesion revascularization was not significantly different between the 2 groups (7.4% versus 7.1%; P =0.8). By a landmark analysis at 1 year, the cumulative incidences of death or myocardial infarction and target-lesion revascularization were also not significantly different between the 2 groups (4.6% versus 5.2%; P =0.46 and 3.3% versus 2.7%; P =0.39, respectively). Conclusions—: Safety and efficacy outcomes of BP-BES were non inferior to those of DP-EES 3 years after stent implantation. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01303640.

This publication has 19 references indexed in Scilit: